

[www.vbsd.at](http://www.vbsd.at)

5<sup>th</sup> | Vienna

Breast Surgery Day

virtual meeting

Tuesday  
16<sup>th</sup> March 2021

09.00 am – 14.15 pm

„SCIENCE  
FROM THE HEART  
OF EUROPE“



**acoasso**  
Österreichische Gesellschaft für Chirurgische Onkologie  
Austrian Society of Surgical Oncology

**esso**  
The European Society  
of Surgical Oncology

**ONCOPLASTIC  
BREAST CONSORTIUM**

**ÖSTERREICHISCHE  
GESELLSCHAFT  
FÜR SENOLOGIE**  
Interdisziplinäres Forum für Brustgesundheit

**NOW YOU CAN  
DISSECT WITH  
PRECISION AND  
A COOL JAW.**

**PRECISION  
IN YOUR  
HANDS.  
EFFICIENCY  
IN YOUR OR.**



Introducing the  
**LigaSure™ LF2019  
Exact Dissector**

© 2020 Medtronic. All Rights Reserved.  
AT 11/2020.

**Medtronic**  
Further. Together

**HORMON REZEPTOR POSITIV  
ECOG PS 1 STADIUM  
LIEBT BRETT SPIELE  
PIK3CA IV  
IST STETS PÜNKTLICH  
MUTATION 63  
POSTMENO PAUSAL  
KANN TOLLE JAHRE  
REDEN HALTEN ALT**



**Ihre Therapie bei PIK3CA-Mutation.**

**PIQRAY®**  
alpelisib

Die **Biomarker-basierte Therapieoption**  
für Ihre HR+/HER2- Brustkrebspatientin mit  
einer **PIK3CA-Mutation** im Tumorgewebe.

**JETZT ZUGELASSEN**

Fachkurzinformation Piqray®

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden. Hinweise zur Meldung von Nebenwirkungen, siehe Abschnitt 4.8 der Fachinformation. **BEZEICHNUNG DES ARZNEIMITTELS** Piqray® 50 mg/150 mg/200 mg Filmtabletten **QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG** Piqray® 50 mg/150 mg/200 mg Filmtabletten: Jede Filmtablette enthält 50 mg/150 mg/200 mg Alpelisib. Liste der sonstigen Bestandteile: Lactosemonohydrat, Mikrokristalline Cellulose, Mannitol (Ph. Eur.), Carboxymethylstärke-Natrium (Typ A) (Ph. Eur.), Hypromellose, Magnesiumstearat (Ph. Eur.) (fälschlich) Rindenzug, Hypromellose, Eisen(III)-oxid (E172), Eisen(II)-oxid (E172), Titandioxid (E171), Macrogol 4000, Talcum. **ANWENDUNGSGEBIETE** Piqray® wird in Kombination mit Fulvestrant angewendet zur Behandlung von postmenopausalen Frauen und Männern mit einem Hormonrezeptor (HR)-positiven, humanen epidermalen Wachstumsfaktorrezeptor2 (HER2)-negativen, lokal fortgeschrittenen oder metastasierten Mammakarzinom mit PIK3CA-Mutation bei Fortschreiten der Erkrankung nach endokriner Therapie als Monotherapie (siehe Abschnitt 5.1 der Fachinformation). **GEGENANZEIGEN** Überempfindlichkeit gegen den Wirkstoff oder einen der oben genannten sonstigen Bestandteile. **PHARMAKOTHERAPEUTISCHE GRUPPE**: Antineoplastische Mittel, andere antineoplastische Mittel, ATC-Code: L01XX05. **INHABER DER ZULASSUNG** Novartis Europharm Limited, Vista Building, Elm Park, Menton Road, Dublin 4, Irland. Rezept und apothekenpflichtig, wiederholte Abgabe verboten. Informationen betreffend Warnhinweise und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkung mit anderen Mitteln, Nebenwirkungen und Gewebungs- effekte sind den veröffentlichten Fachinformationen zu entnehmen. Ausführliche Informationen zu diesem Arzneimittel sind auf den Internetseiten der Europäischen Arzneimittel-Agentur <http://www.ema.europa.eu/> verfügbar. Version: 08/2020

**NOVARTIS**

Novartis Pharma GmbH, Jakob-Lind-Straße 5/Top 3.05, 1020 Wien, [www.novartis.at](http://www.novartis.at)

Datum der Erstellung 12/2020, AT2012226322



Your health  
will change over  
time, but some  
things will always  
endure.

tevapharm.com

NPS-AT-00011

teva

NOVARTIS

Ermöglichen Sie Frauen mit HR+/HER2- aBC



KISQALI®  
Ribociclib

**LEBEN**

Ohne Kleingedrucktes und ohne Wenn und Aber:

**Konsistent überlegenes Gesamtüberleben und verbesserte  
oder erhaltene Lebensqualität  
(in zwei Phase-III-Studien) gegenüber Placebo.<sup>1-6</sup>**

Das kann nur ein CDK4/6 Inhibitor:

KISQALI®

Referenzen: 1. In S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307-316. 2. Slamon DJ, Neven P, Chia S, et al. Overall survival results from the phase 3 MONALEESA-3 study of fulvestrant + ribociclib in postmenopausal patients with HR+/HER2- advanced breast cancer. LBA PR7. Presented at: European Society for Medical Oncology Congress; September 27-October 1, 2019; Barcelona, Spain. 3. Tripathy D, In S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomized phase 3 trial. Lancet Oncol. 2018;19(7):904-915. 4. Fasching PA, Esteva FJ, Pivovarov I, et al. Patient-reported outcomes in advanced breast cancer treated with ribociclib + fulvestrant: results from MONALEESA-3. Presented at: European Society for Medical Oncology Congress; October 19-23, 2018; Munich, Germany. 5. Harbeck N, Vazquez R, Franke R, et al. Ribociclib + tamoxifen or a non-steroidal aromatase inhibitor in premenopausal patients with hormone receptor-positive, HER2- negative advanced breast cancer. MONALEESA-7 patient-reported outcomes. Presented at: European Society for Medical Oncology Congress; October 19-23, 2018; Munich, Germany. 6. Beck JT, Neven P, Esteva FJ, et al. Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2- negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials. P6-18-14. Presented at: San Antonio Breast Cancer Symposium; December 4-10, 2019; San Antonio, USA.

Datum der Erstellung: 05/2020, AT2005R28235

Fachkurzinformation Kisqali®

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden. Hinweise zur Meldung von Nebenwirkungen, siehe Abschnitt 4.8 der Fachinformation. **BEZEICHNUNG DES ARZNEIMITTELS:** Kisqali® 200 mg Filmtabletten **QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG:** Jede Filmtablette enthält Ribociclibsuccinat, entsprechend 200 mg Ribociclib. Sonstige Bestandteile mit bekannter Wirkung: Jede Filmtablette enthält 0,344 mg Phospholipide aus Sojabohnen. **Liste der sonstigen Bestandteile:** Tablettenkern: Mikrokristalline Cellulose, Croscopolidon (Typ A), Hypromellose (5,0-16,0 % m/m Hydroxypropoxy-Gruppen), Magnesiumstearat, Hochdisperses Siliciumdioxid. Filmüberzug: Eisen(II)oxid (E172, schwarz), Eisen(III)oxid (E172, rot), Phospholipide aus Sojabohnen (E322), Polyvinylalkohol, Talkum, Titandioxid (E171), Xanthangummi. **ANWENDUNGSGEBIETE:** Kisqali® wird zur Behandlung von Frauen mit einem Hormonrezeptor/HER2-positiven, humanen epidermalen Wachstumsfaktorrezeptor/HER2-negativen, lokal fortgeschrittenen oder metastasierten Mammakarzinom in Kombination mit einem Aromatasehemmer oder Fulvestrant als initiale endokrinbasierte Therapie oder bei Frauen mit vorangegangener endokriner Therapie angewendet. Bei prä- oder perimenopausalen Frauen sollte die endokrine Therapie mit einem LHRF-Agonisten (LHRF = Luteinizing Hormone-Releasing Hormone) kombiniert werden. **GEGENANZEIGEN:** Überempfindlichkeit gegen den Wirkstoff oder gegen Erythra, Soja oder einen der in Abschnitt 6.1 genannten sonstigen Bestandteile. **Pharmakotherapeutische Gruppe:** Antineoplastische Mittel, Proteinkinaseinhibitoren, ATCCode: L01XE42 **INHABER DER ZULASSUNG:** Novartis European Limited, Vista Building Elm Park, Merion Road, Dublin 4, Irland. **Von 09/2019 Informationen betreffend Warnhinweise und Vorsichtsmaßnahmen für die Anwendung mit anderen Mitteln, Nebenwirkungen und Gewöhnungseffekte sind der veröffentlichten Fachinformation zu entnehmen. Abgabe: Rezept und apothekenpflichtig, wiederholte Abgabe verboten.**

Novartis Pharma GmbH, Jukev-Lind-Straße 5/Top 3.05, 1020 Wien, www.novartis.at

Datum der Erstellung 12/2020, AT201226524

Save  
the  
Date

# 15 INTERDISZIPLINÄRER MAMMA DISKURS

Mittwoch, 13. Oktober 2021

„SCIENCE  
FROM THE HEART  
OF EUROPE“



ÖSTERREICHISCHE  
GESELLSCHAFT  
FÜR SENOLOGIE

Interdisziplinäres Forum für Brustgesundheit

[www.abcsg.at](http://www.abcsg.at)

## SENOLOGIE 2021

35. Jahrestagung der Österreichischen Gesellschaft für Senologie  
9.-11. September 2021  
Scarlaria, St. Wolfgang

**Kongresspräsident:**  
Univ.-Prof. Dr.med.univ. Florian Fitzal, MedUniWien,  
Universitätsklinik für Allgemeinchirurgie

**Kongress-Sekretäre:**  
Dr.med.univ. Christine Deutschmann  
MedUniWien, Universitätsklinik für Frauenheilkunde  
Dr.med.univ. Stefan Konrad  
MedUniWien, Universitätsklinik für Strahlentherapie  
Dr.med.univ. PhD Maximilian Marhold MedUniWien,  
Universitätsklinik für Innere Medizin I  
Dr.med.univ. Stephanie Strobl  
MedUniWien, Universitätsklinik für Chirurgie

**Kongressbüro & Organisation:**  
Wiener Medizinische Akademie Gmbh  
c/o Christian Linzbauer  
1090 Wien, Alser Straße 4  
T: +43 (0)1 405 13 83-17  
F: +43 (0)1 405 13 83-917  
E: [senologie2021@wma.co.at](mailto:senologie2021@wma.co.at)  
[www.medacad.org](http://www.medacad.org)

**Fachausstellung:**  
MAW – Medizinische Ausstellungs- und Werbegesellschaft  
c/o Iris Bobal  
1010 Wien, Freyung 6  
T: +43 (0)1 536 63-48  
F: +43 (0)1 535 60 16  
E: [maw@media.co.at](mailto:maw@media.co.at)  
[www.maw.co.at](http://www.maw.co.at)

[www.senologie.at](http://www.senologie.at)



ÖSTERREICHISCHE  
GESELLSCHAFT  
FÜR SENOLOGIE

Interdisziplinäres Forum für Brustgesundheit

# Index

07	Welcome from the Chair
09 - 11	Scientific Program
12	Our Sponsors
14 - 15	Faculty Map
16 - 23	Faculty (A-Z)

## Congress Organisation

Dr. Elena Kinz  
Public Relations Manager

Austrian Breast & Colorectal Cancer Study Group  
Nussdorfer Platz 8, 1190 Vienna

phone: +43 1 4089230-23  
mobile: +43 664 4379837  
fax: +43 1 4090990  
email: elena.kinz@abcsbg.at

[www.abcsbg.at](http://www.abcsbg.at) | [www.abcsbg.com](http://www.abcsbg.com)

Dr. Silvia Bartl  
Business & Event Manager

Austrian Breast & Colorectal Cancer Study Group  
Nussdorfer Platz 8, 1190 Vienna

phone: +43 1 4089230-12  
mobile: +43 676 9545435  
fax: +43 1 4090990  
email: silvia.bartl@abcsbg.at

[www.abcsbg.at](http://www.abcsbg.at) | [www.abcsbg.com](http://www.abcsbg.com)

Prof. Dr. Florian Fitzal, FEBS, MBA  
Chair

Medical University Vienna, Breast Health Center  
Waehringer Guertel 18-20, 1090 Vienna

email: florian.fitzal@meduniwien.ac.at

[www.ccc.ac.at](http://www.ccc.ac.at) | [www.meduniwien.ac.at](http://www.meduniwien.ac.at)

“SCIENCE  
FROM THE HEART  
OF EUROPE”





**Currently 550 breast surgeons  
and 32 patient advocates from  
79 countries**

## OPBC-01 / iTOP-02: Retrospective multicenter study

- Conventional versus oncoplastic breast conserving surgery
- >3000 patients from 14 breast centers in 8 countries
- Statistical analysis completed

**OPBC-02 / PREPEC:**  
**Randomized controlled trial**

- Pre- versus subpectoral implant-based breast reconstruction after nipple- or skin sparing mastectomy
- 21 breast centers in 7 countries
- 1.8 Mio USD funding from SNF ICT program
- 11 of 372 patients randomized on 31 October 2020

OPBC Consensus Conference 2019 published

THE LANCET  
Oncology

Volume 21, Issue 8, August 2020  
(Pages e375- e385)



## Review

## Knowledge gaps in oncoplastic breast surgery



**Save the dates**

**The next two virtual OPBC events:**

Interactive OPBC Working Group Webinar:

**Thursday, 10 June 2021** (14.00-16.00 CET)

OPBC Consensus Conference 2021  
on strategies for whole breast reconstruction  
with planned radiotherapy:

**Thursday, 2 September 2021** (13.00-17.00 CET)

# Welcome



Local therapy of breast cancer may yield loss of cosmetic integrity and reduce quality of life as the breast is one the most sensible parts of a woman.

Reducing local therapy side effects and increasing the scientific and clinical knowledge about oncoplastic surgery is a clear goal of this meeting. Together with the St. Gallen Breast Cancer Conference taking place within the three days after the Vienna Breast Surgery Day we will set new standards to guide clinical practice in oncoplastic surgery.

We are proud that we were able to launch this event in 2012 in Vienna, as the worldwide medical history of breast surgery has always been deeply connected with the Vienna Medical School as Fritz Demmer was one of the first worldwide pioneers performing breast conservation with radiotherapy in 1920.

The COVID crisis also influenced our meeting and thus we are completely virtual. However, the challenges with COVID19 brought us further regarding digitalising meetings and thus, our team views the current situation as chance to improve social contact and increasing our knowledge faster and all over the world.

Wish you a pleasant time online at the VBSD 2021

Sincerely


Professor Florian Fitzal, MD, FEBS, MBA

President Austrian Society of Senology  
Chief Breast Surgery  
Medical University Vienna



# GEMEINSAM GEGEN KREBS

Starke Kooperation, um neue Standards in der Therapie HER2 positiver Tumore zu setzen



AT-4298; 12/20



**pfm**medical

Quality and Experience

**TiLOOP® Bra Pocket**

**Gebrauchsfertige Netztasche  
zur präpektoralen Brust-  
rekonstruktion**

**Vertrieb Österreich**

mpö pfm GesmbH  
office@mpoe.at

[www.pfmmedical.com](http://www.pfmmedical.com)



# Scientific Program virtual meeting

09.00 – 09.10	<b>Welcome</b> Florian Fitzal
09.10 – 10.50	<b>Experts session "How I do it"</b> Chairs: Michael Knauer (Moderator) and Emil Rutgers (Chat)  This session contains five 15-minute talks, each followed by a 5-minute live discussion.
09.10 – 09.30	<b>NSM classic</b> Jana de Boniface
09.30 – 09.50	<b>Retropectoral reconstruction</b> Peter Schrenk
09.50 – 10.10	<b>Prepectoral reconstruction</b> Marzia Salgarello
10.10 – 10.30	<b>Skin-reducing NSM medial based</b> Zoltán Mátrai
10.30 – 10.50	<b>OBC I &amp; II</b> Florian Fitzal
10.50 – 11.00	<b>Break and Lifetime Achievement Award Presentation</b> presented by Florian Fitzal

11.00 – 12.00

### **Complication management**

Chairs: Michael Gnant (Moderator) and Thomas Helbich (Chat)

This session contains four 10-minute talks,  
each followed by a 5-minute live discussion.

11.00 – 11.15

### **Early complication management in oncoplastic breast conservation**

Peter Schrenk

11.15 – 11.30

### **Early complication management in implant reconstruction**

Roland Reitsamer

11.30 – 11.45

### **Radiological diagnostics for complications**

Maria Bernathova

11.45 – 12.00

### **Late complications after breast reconstruction**

Rupert Koller

12.00 – 13.00

### **NSM Oncology, QoL & Radiology**

Chairs: Peter Dubsky (Moderator) and Michael Hubalek (Chat)

This session contains four 10-minute talks,  
each followed by a 5-minute live discussion.

12.00 – 12.15

### **Radiological workup after NSM**

Thomas Helbich

12.15 – 12.30

### **Oncology & NSM**

Daphne Gschwantler-Kaulich

12.30 – 12.45

### **Radiotherapy in times of prepectoral reconstruction**

Daniela Kauer-Dorner

12.45 – 13.00

### **Measuring QoL after breast cancer surgery**

Maria João Cardoso

13.00 – 13.10

**Break**

13.10 – 14.10

**Scientific visions and upcoming trials**

Chairs: Christian Singer (Moderator) and Christoph Tausch (Chat)

This session contains four 10-minute talks,  
each followed by a 5-minute live discussion.

13.10 – 13.25

**Optimal neoadjuvant treatment options  
to reduce the extent of surgery**

Rupert Bartsch

13.25 – 13.40

**Biomarkers to predict neoadjuvant response**

Zsuzsanna Bágo-Horvath

13.40 – 13.55

**Omitting surgery after neoadjuvant therapy**

Jörg Heil

13.55 – 14.10

**Running trials in oncoplastic surgery**

Paul Weber

14.10 – 14.15

**Farewell**

Florian Fitzal



This event (ID: 699188) was approved  
with 7 DFP points for Medical Education  
from the Austrian Medical Chamber.

## With the kind support of







[www.sg-bcc.org](http://www.sg-bcc.org)

# 18<sup>TH</sup> ST. GALLEN INTERNATIONAL BREAST CANCER CONFERENCE 2023

Primary Therapy of Early Breast Cancer Evidence,  
Controversies, Consensus

15 – 18 March 2023, Vienna/Austria

Save  
the Date

Information: St. Gallen Oncology Conferences (SONK), c/o Tumor and Breast Center ZeTuP  
Rorschacherstrasse 150, 9006 St. Gallen / Switzerland, [info@oncoconferences.ch](mailto:info@oncoconferences.ch), [www.sg-bcc.org](http://www.sg-bcc.org)

**st.galleroncology**  
conferences



**40<sup>th</sup> Congress  
of the European Society  
of Surgical Oncology**

**8 - 10 November 2021**



**esso  
40**


**Lisboa**  
Portugal

**Enhancing the Future  
of Cancer Surgery**



[www.esso40.org](http://www.esso40.org)

# Faculty Map



**Emiel Rutgers**  
Amsterdam

**Jörg Heil**  
Heidelberg

**Walter Paul Weber**  
Basel

**Christoph Tausch**  
Zurich

**Peter Dubsy**  
Lucerne

**Michael Knauer**  
St. Gallen

**Marzia Salgarello**  
Milan

**Maria João Cardoso**  
Lisbon

**5<sup>th</sup> | Vienna**

**Breast Surgery Day**

**16<sup>th</sup> March 2021**

**Jana de Boniface**  
Stockholm

**Roland Reitsamer**  
Salzburg

**Peter Schrenk**  
Linz

**Zsuzsanna Bágo-Horvath**  
Vienna

**Rupert Bartsch**  
Vienna

**Maria Bernathova**  
Vienna

**Florian Fitzal**  
Vienna

**Michael Gnant**  
Vienna

**Daphne Gschwantler-Kaulich**  
Vienna

**Thomas Helbich**  
Vienna

**Daniela Kauer-Dorner**  
Vienna

**Rupert Koller**  
Vienna

**Christian F. Singer**  
Vienna

**Zoltán Mátrai**  
Budapest

**Michael Hubalek**  
Schwaz

## Faculty (A-Z)



### Zsuzsanna Bagó-Horváth

Zsuzsanna Bagó-Horváth, MD, PhD, is associate Professor of Pathology at the Department of Pathology of the Medical University of Vienna. She graduated from the Medical University of Vienna where she also completed her further scientific and resident training. She is a specialized breast pathologist who is a member of the European Working Group for Breast Screening Pathology and the International TILS Working Group. She also functions as a vice secretary for the Austrian Society of Senology and is a member of the General Assembly of the Austrian Breast and Colorectal Cancer Study Group (ABCSCG), where she contributes to clinical studies as a reference pathologist. At the Comprehensive Cancer Center of the Medical University of Vienna, she is a member of the Executive Board of the Breast Care Center. The central subject of her expertise and research are prognostic and predictive factors that govern the progression and therapy response in breast cancer. The combination of histopathology, molecular analyses and animal models facilitate a thorough understanding of how cellular mechanisms contribute to the effect of personalized breast cancer therapy. Together with the ABCSCG, she participated in the validation of multigenomic assays (Endopredict, PAM50-ROR) to aid everyday clinical decisions to offer patients personalized therapy options.



### Rupert Bartsch

Rupert Bartsch is an associate professor of medicine at the Medical University of Vienna, Vienna, Austria, and currently serves as the director of the Breast Cancer Program at the Department of Oncology. Prior to this, he was head of the breast centre at the Elisabethinen Hospital in Linz, Austria, and from late 2017 until March 2018, he was based at the German Breast Group in Neu Isenburg, Germany. Rupert Bartsch has a longstanding clinical and scientific focus on breast cancer. Together with his colleagues, he has published over 150 articles in peer-reviewed journals, among them Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research, and Lancet Oncology.



### Maria Bernathova

Maria Bernathova graduated from Medical school at Komenius-University of Bratislava in 1996 and specialized in the field of Radiology. She was research fellow at „Dimond III” project Digital Mammography, EU project at the Medical University of Innsbruck and was consultant radiologist with special interest in Breast Imaging at Medical University Innsbruck and St. Bernard's Hospital, Gibraltar. In 2013 she graduated in Health Informatics at the →



UMIT - The Health & Life Sciences University in Hall in Tirol with a master's degree. She currently works as Consultant Breast Radiologist at Department of Biomedical Imaging and Image-Guided Therapy 7F, Division of Molecular and Gender Imaging at the Medical University of Vienna, as Breast Consultant at Sanatorium HERA in Vienna and in Privat Klinik Döbling in Vienna. She is furthermore founder of a Privat Clinic for breast health Be-Sure in Vienna. Maria Bernathova's main research interests are women's and breast imaging and health informatics/data science and she published over 40 scientific articles in this research areas.



### **Maria João Cardoso**

Maria João Cardoso is Head Breast Surgeon at the Champalimaud Foundation Breast Unit and Assistant Professor at Nova Medical School in Lisbon. Her main areas of interest are cosmetic outcome and prediction of breast surgery. She is a member of the ESO and ESMO faculty. She is the President of Mama Help, a Portuguese Support Centre for Breast Cancer Patients. She is a member of the EUSOMA executive committee and of the Portuguese Society of Senology. Mj Cardoso is also specialty editor for The Breast.



### **Jana de Boniface**

Jana de Boniface studied medicine at Humboldt University in Berlin and received doctorates at the Medical Faculty of the Charité in Berlin and at the Department of Surgical Sciences of Uppsala University, Sweden. She is a specialized breast cancer surgeon with special focus on oncoplastic and reconstructive breast surgery. She currently holds a position as senior consultant at the Breast Unit of Capio St Göran's Hospital in Stockholm, Sweden and as senior researcher at Karolinska Institute. Her main research focus is on de-escalation of axillary surgery as well as on oncoplastic and reconstructive breast cancer surgery with special focus on oncological safety, patient-reported outcomes and quality of life. Jana de Boniface is a founding member of EUBREAST and Study Group member in the Oncoplastic Breast Consortium (OPBC).



### **Peter Dubsky**

Peter Dubsky is the head of the St. Anna Tumorcenter in Lucerne, Switzerland. He also continues to serve as an adjunct Professor of Surgery at the Medical University of Vienna. In addition to his work in the Consensus Panel of the St. Gallen early breast cancer conference he has established and leads the "Lucerne Toolbox" Consensus: This consensus on surgery after neoadjuvant chemotherapy has recently been published in Lancet Oncology. His primary research interests focus on surgery, adjuvant systemic therapy and biomarker work in early breast cancer.



### Florian Fitzal

Starting in 2003 as a member of the surgical breast unit (General Surgery) Florian Fitzal is currently deputy chief of the Breast Health Center at the Medical University Vienna. Between 2013 and 2016 he was Head of the Breast Health Center, Sisters of Mercy, in Linz Austria with 320 new diagnosed cases per year. He is an international known expert for oncoplastic surgery and breast cancer surgery. As clinical case manager he is involved in the national screening program, diagnosis as well as treatment of early, locally advanced and metastasized breast cancer. He published 143 articles with an h-Index of 24 (Web of Science 08/2018) and he is co-investigator of several prospective clinical trials. Together with his friend Peter Schrenk he published two educational books for oncoplastic surgery which are registered for the European Board of Surgeons Exam UEMS. He is a teacher of the European Board of Surgery, Board member of the Austrian Breast and Colorectal Cancer Study Group (ABCSG) and currently President of the Austrian Society of Senology. As a co-founder of the Oncoplastic Breast Consortium (OPBC) his current scientific goal is to increase clinical trials in oncoplastic surgery.



### Michael Gnant

Michael Gnant is Full Professor of Surgery at the Medical University of Vienna. Gnant graduated in medicine in Vienna, and subsequently specialized in surgery and surgical oncology. He also worked as Visiting Scientist at the National Cancer Institute, National Institutes of Health, Bethesda, USA. He is the author of more than 450 original peer-reviewed papers with an impact factor of 3,400 and an h-index of 69. He is the recipient of multiple national and international awards, and a corresponding member of the Austrian Academy of Sciences. Gnant is involved in many scientific societies including ASCO, AACR, ACS, Breast International Group (BIG), EORTC, ESSO, EUSOMA and UICC. Gnant is also Editor-in-Chief (Breast Care), editorial board member and reviewer for many top-tier peer-reviewed journals including The Lancet, The New England Journal of Medicine, and Journal of Clinical Oncology. Since 2015, he hosts and co-chairs the St.Gallen Breast Cancer Conference in Vienna.



### Daphne Gschwantler-Kaulich

Since 2003, Daphne Gschwantler-Kaulich is a member of the team of Senology at the gynaecological department and the breast cancer center of the Medical University of Vienna. After completing the European Academy of Senology and an adjunct internship at the breast cancer center of Dr. Rezai in 2010 in Düsseldorf, Gschwantler-Kaulich is currently head of the reconstructive breast surgery group at the Department of Gynaecology at the Medical University of Vienna. She is specialized on oncoplastic and reconstructive breast surgery, especially implant-based breast reconstruction, prophylactic bilateral mastectomy with →

immediate reconstruction in BRCA mutation carriers and TX mastectomies. Gschwantler-Kaulich is author and co-author of multiple preclinical and clinical articles in the field of breast cancer and reconstructive breast surgery.



### Jörg Heil

Jörg Heil studied general medicine at the Medical School of the University of Greifswald and Heidelberg, the latter he received his doctorate. He is specialized in gynaecology and habilitated in this field in 2012. Currently, he is head of senology unit at University clinic of women health Heidelberg. He is members of subboard on locoregional/operative studies of German

Breast Group and member of several further medical societies and scientific boards. He is reviewer for numerous peer-reviewed scientific journals (i.e. BioMed Research International, Journal of Oncology, The Breast,...) and authored multiple scientific articles in the field of breast cancer.



### Thomas Helbich

Thomas Helbich MD, MSc, MBA, is professor of Molecular Imaging and Vice Chair of the Department of Biomedical Imaging and Image guided Therapy of the Medical University of Vienna

(<https://radnuk.meduniwien.ac.at/forschung/pil/organisation/>). The main field of research interest are clinical and experimental investigation on

a cellular and sub-cellular level to diagnose cancer, earlier, more accurate, minimal and/or non-invasively. His working group developed and optimized several methods on the basis of MRI, different molecular imaging tools, as well as minimal invasive diagnostic techniques. He is author/coauthor of more than 305 scientific articles. He is PI or Co-PI of several research grants among them four EU grants (VH-PRISM, HYPMED, MURAB, CANCER SCAN). He has been honored with several national and international awards. He is section editor and reviewer of several Medical Journals. He served as the president of several medical societies (EUSOBI, ÖSG, vfwf).



### Michael Hubalek

Michael Hubalek is a certified member of the board of gynecology and obstetrics. He studied at the Medical School of the University of Innsbruck, where he received his doctorate and later his habilitation on „Revisiting Stephen Paget’s „Seed and Soil” Theory – Impact of the „Soil” on the Growth and Progression of Breast Cancer”. He is certified by the european

academy of senology and an accredited breast surgeon. Prof. Hubalek has authored more than 50 scientific articles. His main focus is on new breast cancer surgeries, oncoplastic and reconstructive options for breast cancer. He is currently working and teaching in the Breast Center Schwaz, Austria.



### Daniela Kauer-Dorner

Daniela Kauer-Dorner is part of the Department of Radiotherapy and Biology at the Medical University of Vienna since 1999 and radiotherapeutic expert for breast cancer. From 2000-2002 she participated in an European Educational Program of Radiobiology (Gray Cancer Institute, London; Hospital St. Luc, Brussels, Belgium; University of Leiden, Netherlands; GSF, Munich, Germany) and received a "Master of Radiobiology" degree in 2002. After her return to Vienna she focused on breast cancer, mainly on breast brachytherapy. As part of the GEC ESTRO breast Cancer Working Group she established new techniques of breast cancer brachytherapy at the Medical University of Vienna. Since 2015 she is head of the breast group of the Department of Radiotherapy and Biology. She is member of the European Society for Radiotherapy & Oncology (ESTRO), the Austrian Society of Radiotherapy and the Austrian Society of Senology.



### Michael Knauer

Michael Knauer studied medicine at the Medical University of Innsbruck, where he received his doctorate and later his lecture qualification in surgery. Michael Knauer is a surgeon, specialized on breast cancer and surgical oncology, head of breast surgery and partner at Breast Center Eastern Switzerland in St. Gallen, Switzerland. He is affiliated doctor at Hirslanden Clinic Stephanshorn St. Gallen and furthermore he is member of executive committees of ABCSG, the Swiss Society of Senology and the Swiss breast center certification Q-Label. Michael Knauer is Fellow of the European Board of Surgery since 2010 and author and co-author of multiple preclinical and clinical articles in the field of breast cancer and reconstructive breast surgery, furthermore he is reviewer for numerous peer-reviewed scientific journals and Co-PI of the European Axilla Study TAXIS.



### Rupert Koller

Rupert Koller studied general medicine at the Medical University Vienna, where he received his doctorate and later his habilitation in plastic and reconstructive surgery. Rupert Koller is a surgeon and specialist for plastic, Reconstructive and aesthetic surgery, Head of the Department for Plastic, Aesthetic and Reconstructive Surgery Clinic Ottakring – Wilhelminenspital and the Department of Plastic and Reconstructive Surgery of the Clinic LandstraÙe-Rudolfsstiftung (Vienna Health Association). His research focuses on reconstructive and aesthetic breast surgery, aesthetic and reconstructive and facial surgery, hand surgery and microsurgery, surgery of melanoma and other skin tumors and treatment of acute and chronic wounds. He is designated secretary of the Austrian Society of Senology and member of several other societies and scientific boards, including the Executive Board of the Austrian Society of Plastic, Aesthetic and Reconstructive Surgery and membership of the Ethics Committee of the City of Vienna. Rupert Koller held more than 200 presentations at scientific meetings, continuing education and training courses and published several scientific articles in the field of Breast-, Micro-, Hand- and Burn surgery.





### Zoltán Mátrai

Zoltán Mátrai is a surgeon, specialized in general, thoracic and plastic surgery as well as clinical oncology. Since 2012 he is the Head of Department of Breast and Soft Tissue Surgery and since 2014 also Head of Centre of Surgical Oncology, National Institute of Oncology, Hungary. Dr Mátrai is fellow of the European Board of Surgery in Surgical Oncology and Breast Surgery. Furthermore, he is founder of the Central and Eastern European Breast Cancer Surgical Consortium and President of the Central Eastern European Academy of Oncology. He is currently working on research topics in the field of oncoplastic breast surgery and is interested in treatment optimization of the axilla after sentinel lymph node biopsy, to name just a few. He is a lecturer and trainer for residents, trainees and fellows in breast surgery. He is editor of the textbook Principles and practice of oncoplastic breast surgery, published on Hungarian, English and Russian languages, and author of 98 scientific papers.



### Roland Reitsamer

Roland Reitsamer studied at the Leopold-Franzens-University Innsbruck, was a resident at the University Clinic of Gynecology and Obstetrics Innsbruck and qualified as specialist for gynecology and obstetrics at the University Clinic of Gynecology and Obstetrics Innsbruck. He specialized in breast surgery in 1992, and had several study visits at the MD Anderson Cancer Center, Houston, USA and at the Aultman Cancer Center, Canton, USA. His main scientific surgical interests comprise morbidity reduction in breast surgery, Sentinel node biopsy, breast reconstruction, and nipple-sparing mastectomy. Current position: Chairman of the Department of Senology, Breast Center Salzburg.



### Emiel Rutgers

Emiel Rutgers (1955) gained his medical degree in 1981 from Utrecht University and his PhD degree in 1986 at the University of Amsterdam. Currently, he is a Surgical Oncologist at the Netherlands Cancer Institute in Amsterdam (since 1987), Head of the Department of Surgery (2006 - 2018) and Professor in Surgical Oncology at the University of Amsterdam. Emiel Rutgers is author of more than 700 publications and book chapters on various aspects of breast cancer and beyond. His main fields of interest and research are breast cancer research in prognostic and predictive factors, risk management and prevention, and optimisation of surgical procedures including neo-adjuvant chemotherapy, sentinel node procedure and immediate breast reconstruction. He is principal investigator of the EORTC-AMAROS Trial and the EORTC MINDACT Trial. In 2017 he received the ECCO Clinical Research Award, and in 2019 the Life Time Achievement Award of the ESSO (European Society of Surgical Oncology).



### Marzia Salgarello

Marzia Salgarello is Associate Professor of Plastic Surgery at the Catholic University of "Sacro Cuore", Rome, Italy, where she is in charge of the Plastic Surgery Specialization Course. She is Chief of the Department of Plastic and Reconstructive Surgery of the University Hospital "A. Gemelli", Rome, Italy. Currently she focuses on breast reconstruction and aesthetics, post-oncologic reconstructive microsurgery, and lymphatic surgery. She authored 150 peer-reviewed articles and she is the Editor of the book "Breast reconstruction: current techniques" published by InTech in 2012. She has given presentations at national and international plastic surgery meetings and webinars, especially covering all aspects of breast reconstruction, reconstructive microsurgery, lymphatic surgery, and aesthetic breast surgery. Marzia Salgarello is member and Member of the Board of Directors the Italian Society of Plastic, Reconstructive and Aesthetic Surgery (SICPRE), of the Italian Society of Microsurgery (SIM), of the International Society of Aesthetic Plastic Surgery (ISAPS), of the European Association of Plastic Surgeons (EURAPS), Member and Member of Membership Committee of the World Society for Reconstructive Microsurgery (WSRM) and of the International Society of Plastic Regenerative Surgery (ISPRES).



### Peter Schrenk

Born 1962 in Linz, Austria. Studied medicine in Innsbruck, Basic research: Endothelial cell seeding onto vascular grafts. Medical education at AKH Linz: General practitioner, General Surgery. Spezialization in breast surgery (cancer surgery, reconstruction, cosmetic surgery). Visiting surgeon: European Cancer Institute Milan, Geresheim Düsseldorf, EmoryUniversity Atlanta, Sloan Kettering CC NY, MD Anderson CC Houston, John Wayne CC Santa Monica. Current position: Head of Breast Center, Keplerklinikum Linz. Special interest: Oncoplastic surgery, Implant based breast reconstruction. Co-editor (with Florian Fitzal) of two books on oncoplastic surgery.



### Christian F. Singer

Christian F. Singer is Professor of Clinical-Translational Gynecological Oncology, Head, Center for Familial Breast and Ovarian Cancer, and Head, Vienna Center for Breast Health, Medical University of Vienna, Austria. His scientific interests are Breast cancer and Breast Cancer Genetics, Clinical Trials in Breast Cancer, Breast cancer surgery and reconstruction. Singer is a board-certified gynaecologist and professor at the Medical University of Vienna. After graduation from Innsbruck University Medical School he successfully completed postdoctoral fellowships at the renowned Georgetown University (USA) and at the University of Leuven (Belgium), where he studied the influence of hormones on the development of malignant tumors. In addition, he graduated from Harvard University (USA) where he →

received a “Master of Public Health” degree. Upon his return to Austria, Singer now works and teaches at the Medical University of Vienna, where he has specialized in the treatment of breast cancer and the alleviation of climacteric symptoms. He was appointed Full Professor of Clinical-Translational Gynecological Oncology in 2011 and directs the certified Center for Breast Health at the Department of OB/GYN at Medical University of Vienna. Singer has published numerous scientific articles and book chapters about breast cancer and climacteric symptoms, and has received several national and international awards for his research. He lectures at medical meetings and conferences worldwide. He is married and father of a son.



### Christoph Tausch

Christoph Tausch is clinical director and head of breast surgery of the Breast-Center Zürich/Switzerland since 2017. He received his doctors` degree from the University of Innsbruck/Austria in 1987. He was trained in general surgery and vascular surgery in Linz/Austria. 1991 he started his specialization in breast surgery. In 2016 Tausch became an assistant professor of the University of Innsbruck Medical School. His scientific work is published in more than 70 peer reviewed articles. Tausch is member of EUSOMA, EUBREAST, Austrian Breast Cancer Study Group, Swiss Group for Clinical Cancer Research and Oncoplastic Breast Consortium. Since 2017 he is director of the Swiss Senology Diploma Course.



### Walter Weber

Walter Weber was born in 1973 in New York, studied medicine in Basel, spent more than two years in the lab in the field of tumour immunology at his home University and at the Johns Hopkins Medical Institutions, trained to become a SSO accredited breast surgeon at Memorial Sloan Kettering Cancer Center and currently leads the breast surgery service at the University Hospital Basel. His clinical research interest focuses on oncoplastic surgery and surgical RCT's in the field of surgical site infection and de-escalation of breast cancer surgery. He founded the Oncoplastic Breast Consortium ([www.oncoplasticbc.org](http://www.oncoplasticbc.org)) and co-founded the Basel Breast Consortium ([www.baselbc.org](http://www.baselbc.org)) to build bridges between the laboratories, clinical disciplines and the pharmaceutical industries in the Basel area.

Für Ihr  
Wohl-  
befinden



- ✓ **Erst- und Folgeversorgungen mit Brustprothesen nach Operationen**
- ✓ **Prothesen – BHs und dazu passende Wäsche**
- ✓ **Persönliche und einfühlsame Beratung durch ein Team von ausgebildeten Bandagistinnen**
- ✓ **Verschiedene Brustprothesen-Systeme namhafter Hersteller und neuester Technologien**
- ✓ **Große Auswahl an Formen und Ausführungen für die optimale Passform**
- ✓ **Kompressionsbandagen bei Lymphödem n. Maß**
- ✓ **Verrechnung mit den Österreichischen Sozialversicherungsträgern**

**13x**  
in Ihrer  
Nähe

Weitere Infos auf [www.ortoproban.at](http://www.ortoproban.at)  
oder ☎ **01/402 21 25-6000**

**ORTOPROBAN**

Orthopädie-Technik • Prothesen • Bandagen  
**IHR SANITÄTSHAUS**

» Ich will meinem  
Krebs keine  
Pause gönnen! «

Beim HR+/  
HER2- mBC

**Verzenios**  
abemaciclib



Seit 1.5.2019 in  
der Gelben Box

**VERZENIOS®**  
— Designed to be different —

**Der einzige CDK4 & 6 Inhibitor  
mit kontinuierlicher Gabe\***

\* Abemaciclib unterscheidet sich von den anderen Vertretern dieser Substanzklasse unter anderem durch eine 14-fach selektivere Hemmung von CDK4 gegenüber CDK6\*

1 Verzenios® Fachinformation, Stand Jänner 2020. 2 Chen P, Lee NV, Hu W et al. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Mol Cancer Ther. 2016; 15(10).

*Lilly*

**Kurzinformation**

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden. Hinweise zur Meldung von Nebenwirkungen, siehe Abschnitt 4.8 der Fachinformation. **1. BEZEICHNUNG DES ARZNEIMITTELS:** Verzenios® 50 [100] [150] mg Filmtabletten. **2. QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG:** Jede Filmtablette enthält 50 [100] [150] mg Abemaciclib. Sonstiger Bestandteil mit bekannter Wirkung: Jede Filmtablette enthält 14 [28] [42] mg Lactose-Monohydrat. Vollständige Auflistung der sonstigen Bestandteile, siehe Abschnitt 6.1. **4.1 Anwendungsgebiete:** Verzenios® ist angezeigt zur Behandlung von Frauen mit Hormonrezeptor (HR)-positivem, humanem epidermalen Wachstumsfaktor-Rezeptor-2 (HER2)-negativem lokal fortgeschrittenem oder metastasiertem Brustkrebs in Kombination mit einem Aromatasehemmer oder Fulvestrant als initiale endokrine Therapie oder bei Frauen mit vorangegangener endokriner Therapie. Bei prä- oder perimenopausalen Frauen sollte die endokrine Therapie mit einem LHRH-Agonisten (LHRH = Luteinising Hormone-Releasing Hormone) kombiniert werden. **4.3 Gegenanzeigen:** Überempfindlichkeit gegen den Wirkstoff oder einen der in Abschnitt 6.1 genannten sonstigen Bestandteile. **Pharmakotherapeutische Gruppe:** Antineoplastische Arzneimittel, Proteinkinase-Inhibitoren, ATC-Code: L01XE50. **6.1 Liste der sonstigen Bestandteile:** Tablettenkern: Croscarmellose-Natrium, Lactose-Monohydrat, Mikrokristalline Cellulose, Siliciumdioxid-Hydrat, Natriumstearylfumarat, Filmüberzug: Verzenios 50 mg Filmtabletten Polyvinylalkohol [E1203], Titandioxid [E171], Macrogol [E152], Talkum [E553b], Eisen(II)-hydroxid-oxid x H<sub>2</sub>O [E172], Eisen(III)-oxid [E172], Verzenios 100 mg Filmtabletten Polyvinylalkohol [E1203], Titandioxid [E171], Macrogol [E152], Talkum [E553b], Verzenios 150 mg Filmtabletten Polyvinylalkohol [E1203], Titandioxid [E171], Macrogol [E152], Talkum [E553b], Eisen(II)-hydroxid-oxid x H<sub>2</sub>O [E172]. **7. INHABER DER ZULASSUNG:** Eli Lilly Nederland BV, Papendorpseweg 83, 3528 BJ Utrecht, Niederlande. NR. Apothekenpflichtig. Angaben betreffend Dosierung, Art und Dauer der Anwendung, besonderer Warnhinweise und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstiger Wechselwirkungen, Schwangerschaft, Stillzeit und Fertilität, Nebenwirkungen sowie weitere Informationen entnehmen Sie bitte der veröffentlichten Fachinformation. **Stand:** Jänner 2020.



## Präzise Lokalisierung ohne Draht und Radioaktivität

- 📍 Patientenkomfort ohne Draht
- 📍 Zeitlich flexible Markierung vor OP
- 📍 Optimierter Läsionszugang
- 📍 Innovatives RFID-Minitag
- 📍 Keine Interferenzen im OP-Saal



**HOLOGIC Austria GmbH**

Weyringergasse 6 | 1040 Wien | 01 50466710 [Hologic.at](http://Hologic.at)

ADS-02892-DEU-DE-A Rev001 (01/21) Hologic Inc. Alle Rechte vorbehalten. Hologic, The Science of Sure, Localizer und die zugehörigen Logos sind Marken und/oder eingetragene Marken von Hologic, Inc. und/oder seinen Niederlassungen in den USA und/oder anderen Ländern.

**LOCALIZER™**  
Wire-free Guidance System



**HEICOM.**  
SICHER KOMPLETT VERSORGT

## EIN LEITFADEN FÜR DAS GEWEBE.

**Bioresorbierbare Matrix - GalaFLEX zur Verstärkung des Gewebes der Brust.**

GalaFLEX® ist ein vollständig resorbierbares, monofiles Netz, hergestellt aus P4HB (Poly-4-Hydroxybutyrat) und sorgt für eine längere Festigkeit des Gewebes und verbessert die kosmetischen Ergebnisse.

- Biologisch gewonnen
- Monofil
- Stark
- Bioresorbierbar



**GALATEA**  
SURGICAL

[www.heicom.at](http://www.heicom.at)



# Vertrauen baut auf Stärke

**IBRANCE® für Ihre Patient\*innen  
mit HR+/HER2- metastasiertem  
Brustkrebs (mBC)**



**Weltweite Erfahrungen**  
> 299.000 Patient\*innen seit 2015<sup>1</sup>



**PFS von > 2 Jahren** in der Erstlinie<sup>2</sup>



Erhalt der **Lebensqualität**<sup>3,4</sup>



**Real World Daten** > 4 Jahre Real World  
Erfahrung unterstützt klinische Studiendaten<sup>5</sup>



**1 x 1 Kapsel** täglich

**Referenzen:** 1 Data on file, Pfizer. 2 Finn RS et al, N Engl J Med. 2016;375:1925-36. 3 Harbeck N et al, Ann Oncol. 2016;27(6):1047-54. 4 Rugo HS et al, Ann Oncol. 2018;29(4):888-94. 5 DeMichele A et al, P1-19-02, presented at the SABCS 2019, December 10-14, 2019.

**Abkürzungen:** CDK = Cyclin-abhängige Kinase; HR+/HER2- = Hormonrezeptor-positiv/humaner epidermaler Wachstumsfaktor-Rezeptor-2-negativ; mBC = metastasierter Brustkrebs; PFS = progressionsfreies Überleben.

**Fachkurzinformation:** Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden. Hinweise zur Meldung von Nebenwirkungen, siehe Abschnitt 4.8 der Fachinformation. **IBRANCE 75 mg/100 mg/125 mg Hartkapseln:** Qualitative und quantitative Zusammensetzung: Jede Hartkapsel enthält 75 mg/100 mg/125 mg Palbociclib. Sonstiger Bestandteil mit bekannter Wirkung: Jede Hartkapsel enthält 56 mg/74 mg/93 mg Lactose-Monohydrat. **Liste der sonstigen Bestandteile:** Kapselinhalt: mikrokristalline Cellulose, Lactose-Monohydrat, Carboxymethylstärke-Natrium (Typ A) (Ph.Eur.), hochdisperses Siliciumdioxid, Magnesiumstearat. Kapselhülle: Gelatine, Eisen(III)-oxid (E 172), Eisen(III)-hydroxid-oxid x H<sub>2</sub>O (E 171), Titandioxid (E 171). Drucktinte: Schellack, Titandioxid (E 171), Ammoniaklösung (28 %ige Lösung), Propylenglycol, Simeticon. **Anwendungsgebiete:** IBRANCE ist angezeigt zur Behandlung von Hormonrezeptor (HR)-positivem, humanem epidermalen Wachstumsfaktor-Rezeptor-2 (HER2)-negativem lokal fortgeschrittenem oder metastasiertem Brustkrebs in Kombination mit einem Aromatasehemmer oder in Kombination mit Fulvestrant bei Frauen, die zuvor eine endokrine Therapie erhielten (siehe Abschnitt 5.1 der Fachinformation). Bei prä- oder perimenopausalen Frauen sollte die endokrine Therapie mit einem LHRH-Agonisten (LHRH = Luteinizing Hormone-Releasing Hormone) kombiniert werden. **Gegenanzeigen:** Überempfindlichkeit gegen den Wirkstoff oder einen der in Abschnitt 6.1 der Fachinformation genannten sonstigen Bestandteile. Die Anwendung von Arzneimitteln, die Johanniskraut enthalten (siehe Abschnitt 4.5 der Fachinformation). **Pharmakotherapeutische Gruppe:** Antineoplastische Mittel, Proteinkinase-Inhibitoren. ATC-Code: L01XE33. **Inhaber der Zulassung:** Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Brüssel, Belgien. **Stand der Information:** November 2020. **Rezeptpflicht/Apothekenpflicht:** Rezept- und apothekenpflichtig, wiederholte Abgabe verboten. **Angaben zu besonderen Warnhinweisen und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstigen Wechselwirkungen, Fertilität, Schwangerschaft und Stillzeit und Nebenwirkungen** entnehmen Sie bitte der veröffentlichten Fachinformation.